{"id":"W2902706178","doi":"10.1016/s1470-2045(18)30788-5","title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":548,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Obinutuzumab; Ibrutinib; Chlorambucil; Medicine; Oncology; Internal medicine; Open label; Chronic lymphocytic leukemia; Venetoclax; Clinical trial; Leukemia; Chemotherapy; Cyclophosphamide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001462398,0.001979579,0.003468333,0.0003779269,0.0004069265,0.001551263,0.001166052,0.00165513,0.005730763],"category_scores_gemma":[0.001733493,0.0007009432,0.002485326,0.000450009,0.00125361,0.001186293,0.0005754878,0.003643284,0.001172406],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001186784,"about_ca_system_score_gemma":0.0008955845,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001854729,"about_ca_topic_score_gemma":0.003954011,"domain_scores_codex":[0.9994247,0.000284519,0.00002260446,0.0001014898,0.00003808169,0.0001285815],"domain_scores_gemma":[0.9991668,0.0002557518,0.0001643992,0.0000689516,0.00003927579,0.0003047369],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9818156,0.001803167,0.0003157477,0.0005681472,0.001014634,0.00002866028,0.00005916958,0.0003577573,0.001521963,0.00009603641,0.0006775176,0.01174151],"study_design_scores_gemma":[0.967922,0.02943417,0.001011344,0.00004505476,0.0004501471,0.00003096125,0.00002500306,0.0002207999,0.0001668872,0.0001230134,0.000557553,0.00001313253],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9816235,0.01100809,0.0005463747,0.0008068221,0.000812888,0.001566061,0.001006618,0.0001610399,0.002468675],"genre_scores_gemma":[0.9863256,0.004221749,0.001231057,0.001177878,0.0004564673,0.001775668,0.001290912,0.0000418954,0.003478821],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005730763,"threshold_uncertainty_score":0.01917124,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1690966730335881,"score_gpt":0.4438783636128727,"score_spread":0.2747816905792846,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}